Deep expertise, Broad Impact: How a Specialized CDMO Delivers Value Throughout The Project Lifecycle

Small-molecule API complexity is growing at a pace that is reshaping how drug developers approach manufacturing. The push toward targeted therapies and personalized medicine, the use of artificial intelligence (AI) to design new chemistry, novel mechanisms of action, hazardous and chiral chemistries, and difficult-to-purify compounds are all significantly raising the bar. Many providers offer end-to-end services but lack true specialization in common pain points, risking time and cost. Merck's small-molecule CDMO is committed to dedicated expertise in traditional niche segments—HPAPIs, linker payloads, and functionalized PEGs—alongside tough process characteristics like difficult-to-filter and difficult-to-purify compounds, and underserved areas such as orphan drugs and controlled substances. This session shows how Merck addresses the latest needs of the market by combining deep scientific knowledge with digital, in-silico tools to identify optimal synthetic routes and process parameters to develop fit-for-purpose processes from day one through commercial —without compromising quality, safety, sustainability, or purity.